Manufacturer record
Baxil Pharma Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Baxil Pharma Pvt. Ltd (Uttarakhand) were declared Not of Standard Quality in August 2023. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: 8, Mupirocin Ointment IP (MUPIJAI OINTMENT) (exp Aug 2024). RDTL Chandigarh (state lab) found it not of standard quality: Assay of Mupirocin. Listed in the August 2023 alert.
Records by type
2 records linked to Baxil Pharma Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Mupirocin Ointment IP (MUPIJAI OINTMENT) | Batch 8Mfg Sep 2022 · Exp Aug 2024 | Assay of MupirocinAssay | RDTL ChandigarhState lab | Aug 2023 |
| Levocetirizine and Amrboxol Syrup (C & C Syrup) | Batch BL23015Mfg Feb 2023 · Exp Jan 2025 | Assay of Ambroxol HydrochlorideAssay | RDTL ChandigarhCDSCO lab | Aug 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.